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Abstract
Given the continued high incidence of HIV infection in the United States among racial/ethnic minority young
men who have sex with men (YMSM), and an appreciation that antiretroviral therapy (ART) can provide
personal and public health benefits, attention is needed to enhance the detection of HIV-infected youth and
engage them in medical care and support services that encourage sustained HIV treatment and suppression of
viremia. Poor retention in clinical care has been associated with higher mortality, an increase in HIV RNA, and
decreased CD4 cell count. The goal of the current study was to evaluate the health care utilization and health
outcomes of HIV-infected racial/ethnic minority YMSM enrolled in an outreach, linkage, and retention study
funded by the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB). We hypoth-
esized that among racial/ethnic minority YMSM, baseline CD4 counts and usage of ART are influenced by age,
race, drug and alcohol use, and mental health symptoms. Overall, 155 subjects had at least a baseline CD4 count
recorded at study entry. There was a low rate of ART use in this population with only one-half of the cohort with
CD4 counts £ 350 cells/mm3 being prescribed ART to treat their infection. However, of those youth who were
started on ART, the majority (74%) did achieve undetectable viral loads ( < 400 copies). Given the continued
increase in cases of HIV infection among racial/ethnic minority YMSM, efforts to increase both the provision of
ART and support services that encourage adherence in this population are warranted.
Introduction
To optimize health outcomes, newly diagnosed youthand those already known to have HIV infection must be
effectively linked to care and receive antiretroviral therapy
(ART) as indicated with optimal adherence and suppression
of viral replication. However, an estimated 42–59% of people
living with HIV/AIDS are not in regular HIV care.1 More-
over, despite the widespread availability of HIV screen-
ing programs, delayed diagnosis of HIV infection remains a
substantial problem. Compared to adults, adolescents are
more likely to be identified later in the course of their infection
and delay entry into clinical care.2,3
Poor engagement and retention in care has been found to be
a predictor of higher mortality.4 Further, nonadherence to
medical appointments is associated with both an increased
HIV RNA and a decreased CD4 cell count.5 To date, there is
limited information on clinical outcomes in youth. However,
it has been reported that young adults have poorer rates of
retention in care than older adults, suggesting that young
adults are more at risk for being lost to follow-up.6,7
For HIV-positive patients, adherence to ART to the point of
viral suppression can lower the risks of disease progression
and death,8,9 reduce overall health care costs,10 and, poten-
tially, decrease HIV transmission.11 Despite improvements in
ART regimens with regard to dosing frequency, dosing con-
straints (i.e., food restrictions), storage conditions, and ad-
verse effects,12 drug adherence remains a significant problem.
While current ART regimens are less toxic, more tolerable,
and simpler, suboptimal adherence remains common, and
young age, active drug and alcohol use, and depression are
associated with poor adherence.13–15
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The goal of the current study was to evaluate the health
care utilization and outcomes of HIV-infected young racial/
ethnic minority men who have sex with men (YMSM) en-
rolled in the outreach, linkage, and retention study described
in greater detail previously.16 We hypothesized that among
racial/ethnic minority YMSM, baseline CD4 counts, as a
marker of disease stage, delayed diagnosis of HIV or delayed
entry or re-entry into HIV care, are influenced by age, race,
drug and alcohol use, mental health symptoms, and time
since HIV diagnosis. Further, we anticipated that usage of
ART among racial/ethnic minority YMSM will be less than
recommended by current U.S. Department of Health and
Human Services (DHHS) guidelines17 and influenced by age,
race, drug and alcohol use, and mental health symptoms.
Methods
Study population
Participants for the study were enrolled at one of eight
demonstration sites funded by the Health Resources and
Services Administration’s HIV/AIDS Bureau through its
Special Projects of National Significance (SPNS) program.
These sites were located throughout the U.S. (Bronx and Ro-
chester, NY; Chapel Hill, NC; Chicago, IL; Detroit, MI;
Houston, TX; Los Angeles, CA; and Oakland, CA). Each site
had its own outreach, linkage, and retention strategies. In
order to be eligible for participation in the multisite cohort,
participants had to be born male; HIV-infected and not cur-
rently in care; have sex with men, or the intent to have sex
with men; self-identify as nonwhite, be between the ages of 13
and 24 years at the time of the first interview; be willing and
able to provide full written informed consent; and agree to
release of medical records. For new-to-care participants, three
sites (Bronx, NY; Chapel Hill, NC; and Rochester, NY) en-
rolled youth who were diagnosed with HIV within the past 6
months; one site (Chicago, IL) enrolled youth diagnosed
within the past 3 months; three sites enrolled all youth who
had never been in care (Detroit, MI; Houston, TX; Los An-
geles, CA) and one site (Oakland, CA) only enrolled youth
who had been newly diagnosed within 30 days. Six sites
(Bronx, NY; Chapel Hill, NC; Detroit, MI; Los Angeles, CA;
Oakland, CA; and Rochester, NY) also enrolled youth who
were not new to care but had received either intermittent or no
care for at least 6 months. Institutional Review Boards (IRBs)
of the George Washington University, as well as site-specific
IRBs, approved all instruments and protocols. This included
parent/guardian consent, if required by local IRB.
Data collection
Data for this study were collected between June 1, 2006 and
August 31, 2009. Eligible participants underwent standard-
ized face-to-face interviews by local study staff at baseline and
every 3 months thereafter. Demonstration site administrators
were trained at biannual grantee meetings and then provided
with an interviewer and chart abstraction manual to assist in
training staff. When needed, evaluation and support faculty
conducted site visits for training and quality assurance. All
clinical data were abstracted by trained local personnel. De-
identified data were entered into a secure web-based data
portal by study staff, reviewed for quality, and maintained by
evaluation center staff at The George Washington University.
Statistical analysis
Clinical data were assigned to the appropriate time window
(baseline, 6-month follow-up, 12-month follow-up) based on
the participant’s date of entry into the study. Baseline values
were required to be within 2 months of study entry; 6-month
follow-up values were required to be between 4 and 8 months
after study entry; and 12-month values were required to be
between 10 and 14 months after study entry. If there were two
clinical values within a window, the average of the two was
used for analysis. Any participants who entered the study after
August 31, 2008 were censored since they had less than 1 year
of follow-up time before the end of the study.
Participants were stratified into two groups based on
baseline CD4 counts ( £ 350 and > 350 cells/mm3) and com-
pared by age, race/ethnicity, sexual identity, education, drug
and alcohol use, and depression defined by the Center for
Epidemiologic Studies Depression Scale (CES-D)17a using
Pearson’s Chi-square tests. For those persons with a CD4
count £ 350 cells/mm3 at any time during the first 12 months,
Chi-square tests were used to compare those who started ART
with those who did not start ART on the same set of demo-
graphic and behavioral characteristics. All analyses were
performed using SAS v9.1 (Cary, NC).
Results
There were 227 racial/ethnic minority YMSM who com-
pleted a baseline survey and had at least 1 year of follow-up
time. Overall, 155 subjects (68%) had at least a baseline CD4
count recorded at study entry (Table 1). The only significant
difference between subjects with clinical data and those with-
out was race, with African Americans being more likely than
other races to have clinical data (data not shown). Of the 155
clients, 42 (27%) had only a baseline value, 44 (28%) had
baseline and only 6-month follow-up values, and 69 (45%) had
baseline, 6-month, and 12-month follow-up values. There were
no significant demographic differences between those with
more follow-up data in terms of race, sexual identity, age, site
of enrollment, CES-D score or drug use. The only factor of
significance was that those subjects with more education were
more likely to have follow-up data (data not shown).
There were no significant differences between those subjects
with baseline CD4 counts £ 350 and > 350 cells/mm3 except
that those subjects who were new to care (compared to those
who were re-engaging after intermittent or poor adherence to
medical visits in the past) had higher CD4 counts at baseline
(Table 1). Among those with CD4 counts £ 350 cells/mm3 at
baseline (n = 55), 55% (n = 30) were either on ART or were
prescribed ART the day of enrollment into the study. Of those
on ART, 63% were on an non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based regimen, and 27% on a boosted-
Protease Inhibitor (PI)-based regimen. Regimen information
for 10% of those receiving treatment was not reported.
Among those with CD4 counts £ 350 cells/mm3 at baseline
with at least a 6-month follow-up appointment (n = 40), 27
(67%) were either on or initiated ART at baseline and of those
17 (63%) had an undetectable viral load ( < 400 copies) at their
6-month follow-up. Of the 13 subjects not on ART at baseline,
none were started on therapy at their 6-month follow-up visit
(n = 7) or their 12-month follow-up visit (n = 6).
Among those with CD4 counts > 350 cells/mm3 at baseline
(n = 100), 20 (20%) were either on ART or were prescribed ART
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that day and of those 18 (90%) had an undetectable viral load
at their 6-month follow-up. Thirteen of these 100 clients had a
CD4 count £ 350 cells/mm3 at either or both of their 6- or 12-
month follow-up appointments and of those two (15%) were
started on ART.
Of subjects whose CD4 count was £ 350 cells/mm3 at any
point during the study (n = 67), 48% (n = 32) were either on or
initiated ART (Table 2). Of the 35 subjects who did not initiate
ART, 80% (n = 28) had CD4 counts consistently £ 350 cells/
mm3 at throughout their follow-up. The mean CD4 count
(Standard Deviation, SD) for those who did and did not initiate
ART was 307.0 (SD = 124.3) and 319.2 (SD = 82.3), respectively.
The only significant difference between those who started ART
and those who did not, was that those who started were less
likely to have consumed alcohol on at least 1 day in the 2 weeks
prior to the study visit ( p = 0.05). Of those with at least one
follow-up visit at 6- or 12-months after ART initiation (n = 47),
35 (74%) had an undetectable viral load. There were no sig-
nificant differences between those who did and did not achieve
an undetectable viral load (data not shown).
Table 1. Demographic and Behavioral Characteristics for Racial/Ethnic Minority YMSM






(n = 100) Chi-square test
p valueN (%) N (%)
Site v2 = 8.12
p = 0.322
Los Angeles County, CA 16 (29.1) 18 (18.0)
Chapel Hill, NC 6 (10.9) 25 (25.0)
Bronx, NY 8 (14.6) 20 (20.0)
Detroit, MI 12 (21.8) 13 (13.0)
Harris County, TX 6 (10.9) 13 (13.0)
Chicago, IL 3 (5.5) 4 (4.0)
Oakland, CA 3 (5.5) 5 (5.0)
Rochester, NY 1 (1.8) 2 (2.0)
Age v2 = 4.78
p = 0.092
Less than 19 5 (9.1) 22 (22.0)
19–22 41 (74.6) 68 (68.0)
Older than 22 9 (16.4) 10 (10.0)
Race/ethnicity v2 = 2.34
p = 0.311
African-American 39 (70.9) 73 (73.0)
Other 3 (5.5) 11 (11.0)
Latino/Hispanic 13 (23.6) 16 (16.0)




35 (63.6) 63 (64.3)
Bisexual 13 (23.6) 17 (17.4)
Heterosexual 1 (1.8) 2 (2.0)
Other 6 (10.9) 16 (16.3)
Drug use (ever)
Marijuana 29 (69.1) 67 (74.4) v2 = 0.421
p = 0.517
Other drugs (excludes marijuana and alcohol) 20 (44.4) 40 (43.8) v2 = 0.012
p = 0.915
Drank alcohol at least one day in last 14 days 27 (58.7) 59 (62.8) v2 = 0.216
p = 0.642
Depressive symptomatology (CES-D score at baseline) v2 = 116
p = 0.733
‡16 28 (57.1) 52 (54.2)
<16 21 (42.9) 44 (45.8)
New to Care 28 (50.9) 69 (69.0) v2 = 4.96
p = 0.026
Education v2 = 0.128
p = 0.938
Less than HS 14 (25.5) 26 (26.0)
HS or GED 18 (32.7) 30 (30.0)
Greater than HS 23 (41.8) 44 (44.0)
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Discussion
Overall, there was a low rate of ART use in this population of
racial/ethnic minority YMSM, with one-half of the sample
requiring therapy based on the 2006 DHHS guidelines that re-
commended treatment for asymptomatic patients with CD4
counts £ 350 cells/mm3 and only about one-half of those sub-
jects with an indication for ART receiving it.18 While this number
is low, it is consistent with 2003 data from the Center for Disease
Control and Prevention’s National HIV Surveillance System
project that estimated only 55% of all Americans ages 15–49
living with HIV/AIDS who were eligible for treatment at a
threshold of CD4 count £ 350 cells/mm3 were receiving ART.19
The only predictor we found associated with lack of ART
use was alcohol use in the 2 weeks prior to the study visit.
Physicians are less likely to prescribe ART to patients who
report heavy alcohol use.20 A clear negative effect of alcohol
use on adherence has been previously reported.21–24 A recent
meta-analysis found that those who used alcohol were 50–
60% as likely to be adherent compared to those who ab-
stained.24 These results suggest that more interventions that
target adolescents’ alcohol use in the context of ART are
warranted.
As the pendulum shifts towards earlier initiation of
ART,17,25,26 achieving and maintaining a high degree of adher-
ence is crucial. Incomplete suppression associated with the
Table 2. Baseline Demographic and Behavioral Characteristics for Racial/Ethnic Minority YMSM
Who Had a CD4 Count £ 350 Any Time During the 12 Months of the Study
Started ART
(n = 32)
Did not start ART
(n = 35) Chi-square
test p valueN (%) N (%)
Site v2 = 9.76
p = 0.202
Los Angeles County, CA 10 (31.3) 7 (20.0)
Chapel Hill, NC 3 (9.4) 3 (8.6)
Bronx, NY 3 (9.4) 11 (31.4)
Detroit, MI 7 (21.9) 6 (17.1)
Harris County, TX 5 (15.6) 3 (8.6)
Chicago, IL 0 3 (8.6)
Oakland, CA 3 (9.4) 2 (5.7)
Rochester, NY 1 (3.1) 0
Age v2 = 1.27
p = 0.530
Less than 19 3 (9.4) 5 (14.3)
19–22 25 (78.1) 23 (65.7)
Older than 22 4 (12.5) 7 (20.0)
Race/ethnicity v2 = 0.016
p = 0.992
African-American 23 (71.9) 25 (71.4)
Other 2 (6.3) 2 (5.7)
Latino/Hispanic 7 (21.9) 8 (22.9)
Sexual identity v2 = 1.86
p = 0.394
Gay/homosexual/queer/two spirited 18 (56.3) 24 (70.6)
Bisexual 8 (25.0) 7 (20.6)
Heterosexual 0 0
Other 6 (18.8) 3 (8.8)
Drug use (ever)
Marijuana 16 (64.0) 21 (77.8) v2 = 1.20
p = 0.273
Other drugs (excludes marijuana and alcohol) 13 (50.0) 11 (35.5) v2 = 0.122
p = 0.269
Drank alcohol at least one day in last 14 days 14 (51.9) 23 (76.7) v2 = 3.84
p = 0.0500
Depressive symptomatology (CES-D score at baseline) v2 = 0.134
p = 0.714
‡16 16 (59.3) 18 (54.6)
<16 11 (40.7) 15 (45.5)
New to Care 17 (53.1) 21 (60.0) v2 = 0.321
p = 0.571
Education v2 = 0.107
p = 0.948
Less than HS 8 (25.0) 9 (25.7)
HS or GED 10 (31.3) 12 (34.3)
Greater than HS 14 (43.8) 14 (40.0)
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selection of drug-resistance is clinically important, as virologic
failure increases the risk of subsequent failures due to a de-
creasing number of treatment options. Of those youth who were
started on ART, the majority (74%) did achieve undetectable
viral loads. A review of trials using combination therapy in ART-
naı̈ve patients found levels of virologic success ranging from
51% to 79% for currently utilized NNRTI, or boosted PI regi-
mens in adult cohorts.27 Thus, despite prior studies document-
ing poor adherence among adolescents, we found high levels of
virologic suppression in this cohort. Our success was likely re-
lated to the youth-focused interventions (e.g., case management,
peer counseling, support groups, drop-in clinics) specifically
targeting racial/ethnic minority YMSM at each site.
Prior studies have documented significant differences be-
tween race and virologic efficacy with significantly lower odds
of obtaining virologic suppression in African Americans com-
pared to Whites.28,29 While our sample was small and consisted
of only young gay and bisexual men of color, we did not detect
any differences in demographic features between those who
achieved virologic suppression and those who did not.
In addition to the clear health benefits to individuals
themselves from improved adherence, improvements in ad-
herence are also fundamental to an emerging paradigm called
‘‘test and treat.’’ This paradigm suggests that if all members of
a community who are HIV positive are identified, linked to
care, treated with ART, and achieve viral suppression, the rate
of HIV transmission would be dramatically reduced.30 Thus,
the timely use of ART has important implications for both the
individual and also for public health. Only 44% of our sample
reported using a condom at last episode of anal intercourse.
Moreover, of the 12 YMSM on ART who were not suppressed,
only four (33%) reported using a condom at their last episode
of anal sex. From a public health perspective, nonadherent
and viremic patients likely play a large role in the transmis-
sion of HIV, including drug-resistant HIV strains.31–34
Our study should be considered in light of several limita-
tions. Despite including racial/ethnic minority YMSM from
multiple, geographically diverse locations, the overall sample
size was small and the findings cannot be generalized to the
entire population of racial/ethnic minority YMSM or to other
populations of HIV-infected adolescents such as women and
injection drug users. Moreover, almost one-third of the cohort
did not have clinical data available and were not included in
this analysis. Measurement of retention in care should be
based not just on completion of surveys or attendance at study
visits, but should include appropriate documentation of
provision of clinical care, which consists of having CD4 counts
and viral loads measured every 3–4 months.17 We are unable
to determine whether this lack of data represents a failure of
participants to attend medical visits, a failure of providers to
appropriately order the tests, or a failure of the SPNS dem-
onstration sites to abstract participant clinical data, though
great efforts were undertaken to obtain complete data. It is
possible that those with missing clinical data are subjects
either out of care or inconsistent in attending medical vis-
its, thereby underestimating the severity of disease for this
population.
Based on cumulative observational cohort data demon-
strating the benefits of antiretroviral therapy in reducing
AIDS- and non-AIDS-associated morbidity and mortality, the
DHHS panel now recommends antiretroviral therapy for
adults and adolescents with CD4 counts between 350 and 500
cells/mm3.17 Thus, the number of patients eligible for earlier
initiation of therapy has increased, but the benefits of early
treatment cannot be realized if those who need the medica-
tions are not receiving them. Given the continued increase in
cases of HIV infection among racial/ethnic minority YMSM,
efforts to increase both the provision of ART to this popula-
tion and support services that encourage adherence are
warranted.
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